| Document |
Document Title |
|
WO/2022/203399A1 |
The present invention relates to an antagonist of an adenosine A2A receptor, a pharmaceutical composition containing same for preventing or treating adenosine A2A receptor-related disease (for example cancer), and a method for treating a...
|
|
WO/2022/200594A1 |
The present invention relates to a method for preparing an enantiomerically enriched form of 2-[2-(2-chlorothiazol-5-yl)-2- hydroxy-ethyl]sulfanyl-6-hydroxy-3-methyl-5-phenyl-pyrimidin
-4-one of the formula (I) by hydrogenation of 2-[2-(...
|
|
WO/2022/201097A1 |
Provided herein are compounds and pharmaceutical compositions useful for treating diseases or disorders mediated by the TRPV1 receptor. The present invention also provides methods for treating ocular diseases or disorders by administerin...
|
|
WO/2022/201162A1 |
The present invention provides compounds and pharmaceutical compositions comprising thereof. Further, methods for treating or preventing development of a RNF4 related disorder in a subject in need thereof are also provided.
|
|
WO/2022/203332A1 |
The present invention provides a novel compound having a cyclohexyl-(alkyl or cycloalkyl-substituted)ethylene-amino-heteroaryl moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical co...
|
|
WO/2022/204683A1 |
Disclosed herein are quinazolinyl compounds, compositions, and methods of use thereof. The compounds may be used in the treatment of kinase-related disorders (including cancer, autoimmune disease, and Duchenne muscular dystrophy).
|
|
WO/2022/202864A1 |
The present invention relates to: a compound, or a pharmacologically acceptable salt thereof, that has GLP-1 receptor agonist activity and that is useful as an agent for treating or preventing diseases involving the GLP-1 receptors; and ...
|
|
WO/2022/199661A1 |
Provided is compound of Formula (Y) or Formula (A) or pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of GLP-1 receptor, a pharmaceutical composition comprising...
|
|
WO/2022/200785A1 |
There is provided pharmaceutical compounds of formula I, wherein R1, R2, R3, R4, R6, X, Y, Z, Y1, Y2, Y3 and Y4 have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, i...
|
|
WO/2022/199611A1 |
Provided is a heterocycle substituted ketone derivative, the structure of which is as shown in formula (I). Further provided are a pharmaceutically acceptable salt of the derivative, a stereoisomer thereof, a pharmaceutical composition a...
|
|
WO/2022/199815A1 |
The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 2 (LPA2), particularly the invention relates to compounds that are 8-cyclo-substituted quinazoline derivatives, methods of prepar...
|
|
WO/2022/204227A1 |
The present disclosure relates to compounds that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including h...
|
|
WO/2022/199662A1 |
Provided are a compound represented by general formula (I), or a tautomer, mesomer, racemate, enantiomer, diastereomer or mixture thereof, a deuterium isotopic derivative, pharmaceutically acceptable hydrate, solvate, salt, or eutectic t...
|
|
WO/2022/197763A1 |
The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
|
|
WO/2022/198003A1 |
Described are 6-aryl isoindolin-1-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating ...
|
|
WO/2022/197647A1 |
The present invention is directed to pro drugs of 2-methyl-N-((5-methyl-1,3,4-thiadiazol-2-yl)methyl)-6-(((1S,
2S)-2-(5-methylpyridin-2-yl)cyclopropyl)methoxy)pyrimidin-4-
amine which are useful as therapeutic agents for the treatment of...
|
|
WO/2022/197658A1 |
Compounds that induce expression of ATP-binding cassette transporter Al (ABCA1 ) without lipogenesis are provided, as are methods of using the same to treat or prevent type 2 diabetes or dementia.
|
|
WO/2022/192428A1 |
The present disclosure provides GLP-1R agonists of Formula (I), and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
|
|
WO/2022/188792A1 |
The present invention relates to a compound of formula (I), a pharmaceutical composition comprising same, a preparation method therefor, and a use thereof for preventing or treating tumor-related diseases or conditions.
|
|
WO/2021/174176A9 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
|
WO/2022/188876A1 |
The present application discloses a fused ring heterocyclic compound and an application thereof, and a pharmaceutical composition containing same and an application thereof. In the present application, for the fused ring heterocyclic com...
|
|
WO/2022/188819A1 |
The present invention relates to an SOS1 proteolysis modulator, a preparation method therefor and the application thereof. In particular, the compound of the present invention has a structure represented by formula (I). Further disclosed...
|
|
WO/2022/192533A1 |
Disclosed herein are kinase inhibitory compounds, such as a receptor¬ interacting protein-1 (RIP1) kinase inhibitor compounds of formula (I), as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. ...
|
|
WO/2022/188735A1 |
Provided are heterocyclics as inhibitors of HPK1, in particular a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound that is useful for treatment of HPK1 mediate...
|
|
WO/2022/192430A1 |
The present disclosure provides GLP-1R agonists of formula (I), and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
|
|
WO/2022/192598A1 |
The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, t...
|
|
WO/2022/186133A1 |
In agricultural and horticultural crop production, there is still a great amount of damage due to pests and the like. Thus, the present invention addresses the problem of providing a novel agricultural/horticultural pesticide from the vi...
|
|
WO/2022/183961A1 |
The present application provides an 8-(benzothiazole amide) substituted coumarin compound, a preparation method therefor and an application thereof. The structure of the 8-(benzothiazole amide) substituted coumarin compound is represente...
|
|
WO/2022/185241A1 |
The present invention provides a process of synthesizing 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-(
(2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)eth
ylidene)amino)oxy)cyclopropanecarboxylic acid, including a...
|
|
WO/2022/187568A1 |
Provided herein are salt and crystalline forms of (S)-mepazine, formulations of the same, uses of the same, and processes of preparing (S)-mepazine.
|
|
WO/2022/182547A1 |
This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.
|
|
WO/2022/182152A1 |
The present specification relates to: a compound represented by chemical formula 1 or 2; and an organic light emitting device comprising a first electrode, a second electrode, and one or more organic layers provided between the first ele...
|
|
WO/2022/179528A1 |
Provided are TNIK and/or MAP4K4 kinases inhibitors for the treatment of disease. In one aspect, disclosed herein are kinase inhibitors having a structure of Formula (A), (A*), (I), (IIA), or (IIB). Further described herein are pharmaceut...
|
|
WO/2022/180003A1 |
The present invention provides novel compounds having the general formula: (I) wherein R1, R2, L, and A are as described herein, or a pharmaceutically acceptable salt thereof, compositions including the compounds and methods of using the...
|
|
WO/2022/179608A1 |
Disclosed is use of a multi-target protein kinase inhibitor or a pharmaceutically acceptable salt thereof in preparation a drug for treating or preventing a related symptom caused by one or more of RET, KDR, EGFR, FGFR, FLT, HER, LCK, Ep...
|
|
WO/2022/179529A1 |
Provided are TNIK and/or MAP4K4 kinases inhibitors for the treatment of disease. In one aspect, disclosed herein are kinase inhibitors having a structure of Formulas (A), (A*), (I), (II), (AA), (B), (C), (D), (B*), (C*) and (D*). Further...
|
|
WO/2022/179636A1 |
The present invention relates to crystal forms I, II, III, IV, V, VI, VII, VIII, and IX of an FXR receptor agonist 2-((1S,4S,5R)-5-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxaz
ol-4-yl)methoxy)-2-azabicyclo[2.2.1]heptane-2-yl)benzo[d]thi
...
|
|
WO/2022/178693A1 |
A method for preparing a benzothiazole compound by using N-(2-bromophenyl)thioamide under promotion of visible light, comprising: under the protection of inert gas, adding reactants, N-(2-bromophenyl)thioamide and an inorganic base, into...
|
|
WO/2022/182972A1 |
Disclosed herein are substituted aminopyrimidine compounds of formula I: and pharmaceutically acceptable salts thereof, wherein Ar, R1, and R2 have the meanings described herein; pharmaceutical compositions that include such compounds, a...
|
|
WO/2022/174796A1 |
Disclosed are a pyrimidine compound represented by formula (1) as a Wee-1 inhibitor, a preparation method therefor, and an application of the compound represented by formula (1) and various isomers, crystal forms, pharmaceutically accept...
|
|
WO/2022/177358A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/174526A1 |
Provided are STAT3 small molecule inhibitors, which are naphtho[1,8-cd]isothiazol-5-one-1,1-dioxo derivatives or 1,4-dioxo-5-sulfamoyl-1,4-dihydronaphthalene derivatives. The derivatives are used for preparing medicaments for preventing ...
|
|
WO/2022/175660A1 |
There are provided compounds of formula (I): [hyaluronan production inhibitor]—[labile linker]—X (I), which compounds are useful in the treatment of diseases associated with hyaluronan overproduction.
|
|
WO/2022/177359A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/178283A1 |
Disclosed are compounds and methods for treating tauopathy.
|
|
WO/2022/174525A1 |
The present invention relates to the fields of medicinal chemistry and pharmacotherapeutics, and in particular to a compound, a preparation method therefor and a use thereof, relating to the technical field of pharmacy. Provided are a co...
|
|
WO/2022/174883A1 |
The present invention relates to a compounds of general formula (I) inhibiting both lysophosphatidic acid receptor 1 (LPA1) and receptor 2 (LPA2), particularly the invention relates to compounds that are 5-membered heterocyclyl derivativ...
|
|
WO/2022/177405A1 |
The present invention provides a novel compound, and an organic light-emitting device using same.
|
|
WO/2022/178244A1 |
Described herein are methods and compositions for treating subjects suffering from cancer. In some aspects, herein is described a method of treating a patient suffering from cancer comprising administering to the subject: (i) (R)-2-(1-(6...
|
|
WO/2022/175222A1 |
The present invention relates to cryptophycin compounds, to new cryptophycin payloads, to new cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents.
|
